IMAC Holdings Valuation

Is BACK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BACK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BACK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BACK's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BACK?

Key metric: As BACK is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for BACK. This is calculated by dividing BACK's market cap by their current book value.
What is BACK's PB Ratio?
PB Ratio	-1.4x
Book	-US$1.24m
Market Cap	US$1.79m

BACK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does BACK's PB Ratio compare to its peers?

The above table shows the PB ratio for BACK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.9x
SSY SunLink Health Systems	0.3x	n/a	US$5.3m
TOI Oncology Institute	0.8x	n/a	US$13.0m
USNU U.S. NeuroSurgical Holdings	4.3x	n/a	US$13.6m
IVP Inspire Veterinary Partners	2x	n/a	US$5.8m
BACK IMAC Holdings	n/a	19.7%	US$1.8m

Price-To-Book vs Peers: BACK has negative equity and a Price-To-Book Ratio (-1.4x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does BACK's PB Ratio compare vs other companies in the US Healthcare Industry?

6 Companies	Price / Book	Estimated Growth	Market Cap
ALR AlerisLife	0.3x	63.8%	US$44.14m
LIFW MSP Recovery	0.01x	n/a	US$11.46m
NVOS Novo Integrated Sciences	0.08x	n/a	US$838.40k
BIMI BIMI Holdings	0.01x	n/a	US$104.71k

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: BACK has negative equity and a Price-To-Book Ratio (-1.4x) compared to the US Healthcare industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is BACK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BACK PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-1.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BACK's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.93

1.4%

-15.0%

Lantheus Holdings

US$6.2b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.27

4.4%

28.9%

Sensus Healthcare

US$141.1m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

-3.8%

252.5%